- Home
- Blog Details
This article delves into the transformative potential of genetic testing in extending human lifespan. Departing from prior focuses on musculoskeletal aging, this piece shifts to explore the intricate interplay of genetics in the realms of aging and longevity.
The narrative emanates from a recent Icelandic study revealing that a cluster of 10 to 20 disease-causing gene variants can significantly impact lifespan . As detailed in The New England Journal of Medicine, carriers of these genes may experience a lifespan reduction ranging from three to 15 years compared to noncarriers. The study underscores the importance of early screening and detection to mitigate or potentially prevent the associated lifespan loss.
The crux of the study revolves around "actionable" genes – those linked to diseases for which therapeutic interventions exist. Coined by the American College of Medical Genetics and Genomics (ACMG), actionable genes gained prominence in 2013, serving as markers for potential health risks unrelated to the primary focus of genetic testing.
Focusing on a set of 73 actionable genes released by the ACMG in 2021, the study analyzed whole-genome sequences from 58,000 Icelanders. The research uncovered that 1 in 25 participants carried actionable genes, and these genes, particularly those associated with cancer, exerted a significant impact on life expectancy, reducing it by a median of three years.
Moreover, carriers of actionable genes faced an elevated risk of disease-related mortality. For instance, individuals carrying a pathogenic version of the BRCA2 gene, associated with breast, ovarian, and prostate cancer, had a seven-fold higher risk of dying from these cancers than the general population.
The study not only validated known actionable genes but also unveiled 10 new potentially actionable genes linked to conditions such as chronic kidney disease, blood clotting, bleeding disorders, heart-muscle disease, and maturity-onset diabetes of the young (MODY).
Approximately 4% of the Icelandic population carries actionable genes, a percentage likely mirrored in the United Kingdom and the United States. The article stresses the life-shortening impact of these genes while highlighting the potential for population-wide genetic screening to identify predispositions to various diseases. The power of genetic sequencing lies in its ability to inform personalized disease-prevention and treatment plans, underscoring the importance of early detection and intervention.
As large-scale genetic sequencing tools become more accessible, the article calls for increased political will and policy support for initiatives like the All of Us research program. Until then, individuals are encouraged to advocate for genetic tests, potentially unlocking additional years of life through informed healthcare decisions."
